Streetbeat News

Revenues

ALLY

Seven analysts have recently published ratings on Ally Financial (NYSE:ALLY), with a mix of bullish to bearish sentiments. Over the past three months, ratings have included 2 bullish, 1 somewhat bullish, 3 indifferent, and 1 somewhat bearish, with no bearish ratings. The 12-month price targets show an average of $36.29, a high of $47.00, and a low of $28.00, indicating a 19.65% increase from the previous average target of $30.33. Analysts from firms like Wells Fargo, Deutsche Bank, Barclays, Goldman Sachs, Morgan Stanley, Wolfe Research, and TD Cowen have adjusted their ratings and price targets, reflecting their views on Ally Financial's market position and financial performance. Ally Financial, a major consumer auto lender, has a diversified business model but has seen a -1.41% decline in revenue growth as of September 30, 2023, and faces challenges in ROE and ROA, despite a strong net margin and prudent debt management.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 3:00 pm

ADMA

ADMA Biologics (NASDAQ:ADMA) received mixed analyst ratings in the latest quarter, with 4 analysts offering views. The average 12-month price target is $6.5, up from $6.00, with a high of $9.00 and a low of $5.00. Analysts from Mizuho and HC Wainwright & Co. raised their price targets, while Cantor Fitzgerald maintained its rating. ADMA Biologics is a biopharmaceutical company focusing on plasma-derived biologics for immunodeficient patients. The company's financials show a revenue growth of 63.72%, a net margin of 3.81%, ROE of 1.72%, ROA of 0.74%, and a debt-to-equity ratio of 1.01.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 3:00 pm

MULN

Mullen Automotive, Inc. has delivered and invoiced 130 additional Class 1 EV cargo vans to Randy Marion Automotive Group for $4,372,550. This brings the total delivered to 230 vans out of the initial 1,000 vehicle order, totaling $7,736,150 in invoices. The Mullen ONE vans are designed for last-mile delivery with a 110-mile range and are produced in Tunica, Mississippi. The company anticipates a strong year for its commercial EV efforts.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:16 pm

FNGR

FingerMotion, Inc. (NASDAQ:FNGR) provided supplemental quarterly guidance, indicating variability in quarterly revenue recognition due to the sporadic nature of its business segments. For the nine months ended November 30, 2023, revenue was $27.6 million, a 30% increase year-over-year, with gross profit rising 90% to $3.1 million. The company's CEO, Martin Shen, emphasized the importance of focusing on long-term trends rather than short-term fluctuations, highlighting the company's diverse portfolio and adaptive strategies for future growth.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:13 pm

GFS

IFNNY

Infineon Technologies AG and GlobalFoundries have extended their long-term agreement to supply AURIX™ TC3x 40 nanometer automotive microcontrollers, power management, and connectivity solutions. This partnership, which began in 2013, focuses on automotive, industrial, and security semiconductor technology. The agreement secures additional capacity for Infineon's business growth from 2024 to 2030 and supports the transition towards autonomous, connected, and electrified vehicles. The collaboration emphasizes the importance of a resilient supply chain and innovation in the automotive industry.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:06 pm

VIRI

Virios Therapeutics is progressing the development of IMC-2 for treating symptoms associated with Long-COVID. This move could potentially address the needs of patients suffering from persistent symptoms after recovering from the initial COVID-19 infection.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:03 pm

EYPT

EyePoint Pharmaceuticals (NASDAQ:EYPT) has been evaluated by 7 analysts over the last three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $31.71, up 18.54% from the previous $26.75, with a high estimate of $44.00 and a low of $20.00. Recent analyst actions include ratings and price target adjustments by JP Morgan, HC Wainwright & Co., Capital One, and Mizuho. EyePoint Pharmaceuticals focuses on ophthalmic products and has shown a revenue growth of 51.84% as of September 30, 2023. However, it has a net margin of -82.96% and an ROE of -21.77%, indicating profitability challenges.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 2:01 pm

WDAY

Workday (NASDAQ:WDAY) has been the subject of 20 analyst ratings over the past three months, with sentiments ranging from bullish to bearish. The average 12-month price target for WDAY is $286.7, with a high of $330.00 and a low of $245.00, indicating an 11.66% increase from the previous average of $256.76. Analysts have recently adjusted their ratings and price targets, with many maintaining or raising their outlooks. Workday's financial performance shows strong revenue growth but below-average net margin, ROE, and ROA, with a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 2:01 pm

KKR

KKR & Co (NYSE:KKR) has received varied analyst ratings over the last quarter, with an average 12-month price target of $85.62, reflecting a 10.12% increase from the previous target. Analysts from firms like Wells Fargo, Keefe, Bruyette & Woods, and Morgan Stanley have raised their price targets, indicating a positive outlook on the company's performance. KKR is a major alternative asset manager with significant AUM and has shown strong financial health with high revenue growth and net margin, although its ROA and debt-to-equity ratio raise some concerns.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 2:00 pm

ROP

In the last three months, 6 analysts have published diverse ratings on Roper Techs (NASDAQ:ROP), with 4 somewhat bullish and 2 indifferent. The average 12-month price target is $564.17, up 2.69% from the previous target. Analysts from Wells Fargo and RBC Capital raised their price targets, while TD Cowen and Mizuho maintained or raised their ratings with different price targets. Roper is a diversified tech company focusing on software and technology-enabled products, with strong revenue growth and net margin but below-average ROE and ROA.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 2:00 pm